scholarly journals Osteopontin Serum Concentration and Metabolic Syndrome in Male Psoriatic Patients

2021 ◽  
Vol 10 (4) ◽  
pp. 755
Author(s):  
Joanna Bartosińska ◽  
Joanna Przepiórka-Kosińska ◽  
Beata Sarecka-Hujar ◽  
Dorota Raczkiewicz ◽  
Małgorzata Kowal ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Serum Concentration ◽  
Low Density Lipoprotein ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Enzyme Linked Immunosorbent Assay ◽  
Multifunctional Protein ◽  
Inflammatory Processes ◽  
Lipid Abnormalities

Psoriasis (Ps) is an immune-mediated inflammatory skin disease that is widely associated with the clinical features of metabolic syndrome (MetS), including hypertension, abdominal obesity, insulin resistance, type 2 diabetes and dyslipidemia. Osteopontin (OPN), a multifunctional protein involved in the modulation of inflammatory processes, may contribute to the development of atherosclerosis and MetS. Therefore, the aim of the study was the assessment of the correlation between OPN concentration in the peripheral blood and the presence of MetS as well as its particular components in the Ps patients. The study comprised 107 male Ps patients (50 patients with MetS and 57 without MetS) and 38 healthy volunteers (HVs). The concentration of OPN in serum was determined using enzyme-linked immunosorbent assay (ELISA) method. Fasting blood glucose and lipid profile components: total cholesterol (total CHOL), high-density lipoprotein cholesterol (HDL-CHOL), low-density lipoprotein cholesterol (LDL-CHOL), triglycerides (TG) were examined. Ps patients with MetS had significantly higher obesity, systolic blood pressure, TG, CHOL/HDL, LDL/HDL and TG/HDL ratios than Ps patients without MetS. OPN serum concentration was significantly higher in the Ps patients than in the HVs (p = 0.022) but not significantly different between the Ps patients with and without MetS (p = 0.275). OPN serum concentration in Ps patients correlated negatively with total CHOL (p = 0.004) and TG (p = 0.009). OPN is increased in Ps patients and may serve as a biomarker of some lipid abnormalities in them.

scholarly journals ASSOCIATION OF SUBCLINICAL HYPOTHYROIDISM IN METABOLIC SYNDROME PATIENTSASSOCIATION OF SUBCLINICAL HYPOTHYROIDISM IN METABOLIC SYNDROME PATIENTS

2018 ◽  
Vol 11 (9) ◽  
pp. 188
Author(s):  
Jennifer S Suhashini ◽  
Savitha G
Keyword(s):  
Metabolic Syndrome ◽  
Subclinical Hypothyroidism ◽  
Low Density Lipoprotein ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Significant Difference ◽  
Tsh Levels

Objectives: Subclinical hypothyroidism (SCH) is also the major risk for cardiovascular disease like metabolic syndrome (MetS). Hence, the aim of this study is to assess the association of SCH in MetS patients.Materials and Methods: Ninety patients reporting to Saveetha Dental College and Hospitals were enrolled in the study which includes 40 patients with MetS and 40 healthy individuals. 5 ml of venous blood was collected and centrifuged. Then, it is analyzed for fasting blood sugar, serum triglycerides, high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), and very low-density lipoprotein (VLDL) using the standard kit method. Then, Free T3, Free T4, and thyroid-stimulating hormone (TSH) were estimated by ELISA method. The data obtained were subjected to statistical analysis using the SPSS software.Results: SCH is 20% in cases when compared to 4.4% in controls, which was significant, p=0.024. The biochemical parameters were compared between the study population fasting blood glucose, triglycerides, total cholesterol, low-density lipoprotein cholesterol, and VLDL cholesterol was statistically significant, with p<0.001. TSH levels showed significant difference between two groups with the p=0.002.Conclusion: MetS patients should be screened for the SCH as an important risk factor in evaluation protocol. Mere correction of TSH levels can reverse the associated morbidity in these patients rather than leaving them untreated pushing them to a state of overt hypothyroidism with its attendant complications.

scholarly journals Serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters

2019 ◽  
Author(s):  
SELMA KORKMAZ ◽  
GÜLBEN SAYILAN ÖZGÜN
Keyword(s):  
Metabolic Syndrome ◽  
Metabolic Regulation ◽  
Psoriasis Vulgaris ◽  
Fasting Blood Glucose ◽  
Multivariate Logistic Regression Analysis ◽  
Density Lipoprotein ◽  
Metabolic Parameters ◽  
Lipoprotein Cholesterol ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group

Background/aim: Adropin is a peptide-structure hormone that plays a role in preventing the development of insulin resistance, which has been linked to obesity and metabolic regulation. The purpose of this study is to assess serum adropin levels and their relationship with metabolic parameters in psoriasis vulgaris patients both with and without metabolic syndrome (MetS). Methods: Fifty-three patients and twenty-six healthy controls were included in this study. Serum adropin levels, fasting blood glucose, fasting plasma insulin, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, total cholesterol, and triglyceride levels of all participants were analyzed. Enzyme-linked immunosorbent assay was used to measure serum adropin levels. Results: Serum adropin levels in psoriatic patients without MetS were 2.94±0.56 ng/ml, in psoriasis patients with MetS were 2.49±0.77 ng/ml and were 3.37±0.71 ng/ml in control group. Multivariate logistic regression analysis was used to evaluate adropin decreases in psoriasis patients as an independent predictor in terms of the presence of MetS. Conclusion: The serum levels of adropin in psoriasis patients were significantly lower in the presence of MetS, and this decrease was more prominent than in those without MetS. Adropin may be a responsible factor for metabolic disorders and the development of MetS in psoriasis patients. Key words: Psoriasis, metabolic syndrome, adropin

Astaxanthin Supplementation Lowers Dietary Intake in Healthy Subjects

2020 ◽  
Vol 19 (1) ◽  
pp. 46-51
Author(s):  
Chuenjai Sratongfaeng ◽  
Nithipun Suksumek ◽  
Nithikoon Aksorn ◽  
Pithi Chanvorachote ◽  
Kulwara Meksawan
Keyword(s):  
Dietary Intake ◽  
Controlled Trial ◽  
Low Density Lipoprotein ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Health Indicators ◽  
Lipoprotein Cholesterol ◽  
Blood Levels ◽  
Biological Parameters ◽  
Dietary Intakes

Astaxanthin, a potent antioxidant compound, is well recognized for its beneficial effects to protect from oxidative stress and free radicals. However, the effects of long period of use of astaxanthin on biological parameters, health indicators, and energy intake are still largely unknown. A total of 33 healthy participants aged 21–54 years with body mass index in the range of 18.50−24.90 kg/m2 were enrolled in this randomized controlled trial and were assigned into astaxanthin and placebo groups. The participants in the astaxanthin group received 4 mg of astaxanthin once daily for 12 consecutive weeks. Dietary intakes, as well as blood levels of astaxanthin and biological parameters, were investigated at baseline and week 12. The significant elevation of blood astaxanthin level in the astaxanthin group was notified at week 12. Regarding basic characteristics of blood biochemical parameters, results indicated that the fasting blood glucose, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol were not significantly different between astaxanthin and placebo groups at week 12. Interestingly, the significant decrease in total energy and carbohydrate intakes of the participants in the astaxanthin group (P < 0.05) was found after 12-week supplementation, compared to the baseline. The findings support the safety of long-term supplementation and reveal potential dietary intake lowering effect of astaxanthin in healthy individuals.

scholarly journals Relationship between C-reactive protein and features of the metabolic syndrome in military pilots in the Serbia and Montenegro

2005 ◽  
Vol 62 (11) ◽  
pp. 811-819
Author(s):  
Aleksandra Jovelic ◽  
Goran Radjen ◽  
Stojan Jovelic ◽  
Marica Markovic
Keyword(s):  
Metabolic Syndrome ◽  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
C Reactive Protein ◽  
Low Density Lipoprotein Cholesterol ◽  
Reactive Protein

Background/Aim. C-reactive protein is an independent predictor of the risk of cardiovascular events and diabetes mellitus in apparently healthy men. The relationship between C-reactive protein and the features of metabolic syndrome has not been fully elucidated. To assess the cross-sectional relationship between C-reactive protein and the features of metabolic syndrome in healthy people. Methods. We studied 161 military pilots (agee, 40?6 years) free of cardiovascular disease, diabetes mellitus and active inflammation on their regular annual medical control. Age, total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, triglycerides, fasting glucose, glycosylated hemoglobin, blood pressure, smoking habit, waist circumference and body mass index were evaluated. Plasma C-reactive protein was measured by the immunonephelometry (Dade Behring) method. Metabolic syndrome was defined according to the National Cholesterol Education Program Expert Panel. Results. The mean C-reactive protein concentrations in the subjects grouped according to the presence of 0, 1, 2 and 3 or more features of the metabolic syndrome were 1.11, 1.89, 1.72 and 2.22 mg/L, respectively (p = 0.023) with a statistically, significant difference between those with 3, and without metabolic syndrome (p = 0.01). In the simple regression analyses C-reactive protein did not correlate with the total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, body mass index and blood pressure (p > 0.05). In the multiple regression analysis, waist circumference (? = 0.411, p = 0.000), triglycerides to high density lipoprotein cholesterol ratio (? = 0.774, p = 0.000), smoking habit (? = 0.236, p = 0.003) and triglycerides (? = 0.471, p = 0.027) were independent predictors of C-reactive protein. Conclusions. Our results suggested a cross-sectional independent correlation between the examined cardiovascular risk factors as the predominant features of metabolic syndrome and C-reactive protein in the group of apparently healthy subjects. The lack of correlation of C-reactive protein with the total cholesterol and low density lipoprotein cholesterol in our study may suggest their different role in the process of atherosclerosis and the possibility to determine C-reactive protein in order to identify high-risk subjects not identified with cholesterol screening.

scholarly journals ASSOCIATION BETWEEN BLOOD LIPID PROFILE AND BLOOD GLUCOSE LEVELS IN MEN WITH CORONARY HEART DISEASE, METABOLIC SYNDROME, AND TYPE 2 DIABETES MELLITUS

2013 ◽  
Vol 12 (5) ◽  
pp. 29-33
Author(s):  
S. A. Matveeva
Keyword(s):  
Blood Glucose ◽  
Lipid Profile ◽  
Low Density Lipoprotein ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Blood Lipid ◽  
Lipoprotein Cholesterol ◽  
Blood Lipid Profile ◽  
Glucose Levels ◽  
Blood Glucose Levels

Aim.To study the associations between blood lipid profile and blood glucose levels in men with coronary heart disease (CHD), stable effort angina (SEA), metabolic syndrome (MS), and Type 2 diabetes mellitus (DM-2).Material and methods.The study included 82 men (mean age 50,5±0,9 years) with CHD, Functional Class I–III SEA, MS, and DM-2. The following lipid profile parameters were assessed: total cholesterol (TCH), triglycerides (TG), low-density lipoprotein cholesterol (LDL–CH), very low-density lipoprotein cholesterol (VLDL–CH), high-density lipoprotein cholesterol (HDL–CH), atherogenic index (AI), and triglyceride index (TGI), together with fasting blood glucose.Results.There were positive (direct) associations between higher levels (>90th percentile) of lipid profile parameters (TCH, TG, LDL–CH, VLDL– CH, HDL–CH, AI, TGI) and blood glucose, as well as between lower levels (≤10th percentile) of lipid profile parameters (TCH, TG, LDL–CH, VLDL– CH, AI, TGI) and blood glucose. At the same time, there were negative (inverse) associations between lower lipid levels (≤10th percentile of TCH, TG, LDL–CH, VLDL–CH, HDL–CH, AI, TGI) and higher glucose levels (>90th percentile), as well as between higher lipid levels (>90th percentile of TCH, TG, LDL–CH, VLDL–CH, HDL–CH, AI, TGI) and lower glucose levels (≤10th percentile).Conclusion.Dyslipidemia and hyperglycemia demonstrate synergetic proatherogenic effects in patients with CHD, SEA, MS, and DM-2, as suggested by significant heterogeneous (direct and inverse) associations between lipid profile parameters and fasting blood glucose. The results obtained provide an opportunity for the assessment of risk levels, prognosis, and need for pharmacological prevention and treatment in patients with combined cardiovascular pathology. 

scholarly journals Validation of the Friedewald Formula in Patients with Metabolic Syndrome

Cholesterol ◽  
2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
José Knopfholz ◽  
Caio César Diniz Disserol ◽  
Andressa Jardim Pierin ◽  
Fernanda Letícia Schirr ◽  
Larissa Streisky ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Statistical Significance ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Good Method ◽  
Lipoprotein Cholesterol ◽  
Blood Cholesterol ◽  
Final Report ◽  
Direct Assay ◽  
Friedewald Formula

Currently, the Friedewald formula (FF) is the main method for evaluating low-density lipoprotein cholesterol (LDL-c). Recently, many limitations have emerged regarding its use, including patients with triglyceride levels ≥400 mg/dL, diabetes mellitus, and kidney or hepatic chronic diseases. We analyzed the use of the FF in patients with metabolic syndrome. We selected patients with known metabolic syndrome that fulfilled the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report and excluded patients with triglyceride levels ≥400 mg/dL and chronic liver and/or kidney disease. Using direct assays, we measured total cholesterol, high-density lipoprotein cholesterol, triglycerides, and LDL-c. Then, LDL-c was estimated using the FF and compared with the LDL-c by direct assay. The sample size was 135 patients. Using the FF, the mean LDL-c value was 124.4±42.1 mg/dL; it was 125.1±38.5 mg/dL by direct assay. The correlation coefficient between these two methods was 0.89, with statistical significance (P  value<0.001). There were no significant differences between the patients with triglyceride levels >150 mg/dL (P=0.618). In conclusion, FF is a good method for estimating LDL-c in patients with metabolic syndrome.

Sign in / Sign up

Export Citation Format

Share Document